Cmed and Larix fully integrate into Aixial Group Press release – May 30th 2023 Following its acquisition of Larix in…
Rare Diseases: Phase I First-in-Human Study on Wilson’s Disease Case study This case study looks at the challenges that arose…
Cell & Gene Therapy: Safety and Clinical Activity in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Case…
Rare Diseases: Phase II Pediatric Study with Selected Metabolic Disorders Case study Aixial Group is currently working on a Phase…
Data Science & Analytics: Combining A Phase I Study with an On-Going Observational Study Case study This case study looks…
Early Phase Oncology: First-In-Human Study Of An Antibody-Drug Conjugate In Breast Cancer Case study For a First In Human study,…
Early-Phase Oncology: First-In-Human Study in Advanced Solid Tumors Case study For a First In Human study, site activation and enrollment…
Rare Diseases: Phase II Primary Biliary Cholangitis Case study Rare disease research can be challenging and often there are no…
Efficient Publication Strategy Leads to Expedited Submission and Acceptance Case study Since the World Health Organization (WHO) launched the Global…
Navigating the latest ICH E8(R1) Guideline Revisions Becoming fully compliant with the latest and soon-to-be released ICH E8(R1) guidance documents…
RBQM for Decentralized Trials: Two key areas of focus to reduce your risk Since ICH-GCP E6 R2 made Risk-Based Quality…
Aixial FSP models: Expand your data management and biostatistics capabilities Whatever your existing study team structure and study data output…
